Insider Transactions in Q2 2021 at Intercept Pharmaceuticals, Inc. (ICPT)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 30
2021
|
Mark Pruzanski Director |
SELL
Payment of exercise price or tax liability
|
Direct |
3,816
-0.62%
|
$72,504
$19.97 P/Share
|
|
Jun 30
2021
|
Mark Pruzanski Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,136
+0.99%
|
$116,584
$19.97 P/Share
|
|
Jun 21
2021
|
Andrew Saik EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
52,156
+50.0%
|
-
|
|
Jun 14
2021
|
M Michelle Berrey President, R&D and CMO |
BUY
Grant, award, or other acquisition
|
Direct |
67,118
+50.0%
|
-
|
|
May 28
2021
|
Mark Pruzanski Director |
SELL
Payment of exercise price or tax liability
|
Direct |
3,817
-0.63%
|
$61,072
$16.63 P/Share
|
|
May 28
2021
|
Mark Pruzanski Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,138
+1.0%
|
$98,208
$16.63 P/Share
|
|
May 27
2021
|
Srinivas Akkaraju Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,029
+18.91%
|
-
|
|
May 27
2021
|
Luca Benatti Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,029
+28.37%
|
-
|
|
May 27
2021
|
Daniel Bradbury Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,029
+30.78%
|
-
|
|
May 27
2021
|
Dagmar Rosa Bjorkeson Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,543
+50.0%
|
-
|
|
May 27
2021
|
Fundaro Paolo Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,029
+20.03%
|
-
|
|
May 27
2021
|
Keith Michael Gottesdiener Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,029
+29.27%
|
-
|
|
May 27
2021
|
Nancy Miller Rich Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,029
+32.55%
|
-
|
|
May 27
2021
|
Gino Santini Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,029
+30.64%
|
-
|
|
May 27
2021
|
Glenn Sblendorio Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,029
+30.91%
|
-
|
|
May 15
2021
|
Linda M Richardson EVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
171
-0.64%
|
$3,078
$18.15 P/Share
|
|
May 12
2021
|
Gail Cawkwell SVP, Med Affairs, Safety & PV |
SELL
Payment of exercise price or tax liability
|
Direct |
319
-0.97%
|
$5,423
$17.75 P/Share
|
|
May 08
2021
|
David A Ford Chief Human Resources Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
128
-0.54%
|
$2,176
$17.15 P/Share
|
|
Apr 30
2021
|
Mark Pruzanski Director |
SELL
Payment of exercise price or tax liability
|
Direct |
3,817
-0.75%
|
$72,523
$19.78 P/Share
|
|
Apr 30
2021
|
Mark Pruzanski Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,138
+1.2%
|
$116,622
$19.78 P/Share
|
|
Apr 01
2021
|
Jerome Benedict Durso CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
289
-0.35%
|
$6,936
$24.28 P/Share
|
|
Apr 01
2021
|
David A Ford Chief Human Resources Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
92
-0.38%
|
$2,208
$24.28 P/Share
|
|
Apr 01
2021
|
Rocco Venezia Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
29
-0.2%
|
$696
$24.28 P/Share
|
|
Apr 01
2021
|
Christian Weyer EVP, Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
46
-0.17%
|
$1,104
$24.28 P/Share
|